Low levels of folate may increase dementia risk: research

Wednesday, 16 March, 2022

Low levels of folate may increase dementia risk: research

Low levels of folate (vitamin B9) in the blood may be linked to a heightened risk of dementia and death from any cause in older people, reveals new research.

Levels should be routinely monitored and deficiencies corrected in older age, especially given that blood levels of folate tend to tail off with age, with up to 1 in 5 older adults estimated to be folate deficient, say the authors of new research published in the journal Evidence Based Mental Health.

The evidence to date suggests that folate deficiency affects cognition and nerve signalling in the brain, making it a possible risk factor for subsequent dementia. But the few studies that have looked at this have included small numbers of participants and produced mixed results.

And because of the time it takes for dementia to develop, it’s been difficult to rule out reverse causation, whereby folate deficiency could be a consequence of pre-clinical dementia rather than its cause, they add.

They therefore wanted to see if serum folate deficiency might be linked to the risks of incident dementia and death from any cause in a large national sample of older adults, and to include the potential role of reverse causation.

Researchers drew on the medical records of 27,188 people served by one national healthcare provider in Israel. All the participants were aged between 60 and 75, and had had no pre-existing dementia for at least 10 years before blood folate checks began in 2013. Their records were monitored for a diagnosis of dementia or death up to the end of 2017.

Some 3418 (just under 13%) participants were folate deficient, defined as levels below 4.4 ng/mL. Folate deficiency was associated with a substantially heightened risk of both dementia and death from any cause.

Among those who were folate deficient, the incidence of dementia was estimated at 7.96 per 10,000 person years, while death from any cause was estimated at 19.20 per 10,000 person years.

This compares with an estimated dementia incidence of 4.24 and of death from any cause of 5.36 per 10,000 person years among those who weren’t folate deficient.

In percentage terms, rates of dementia were almost 3.5% and of death from any cause just under 8% among those with folate deficiency. This compares with dementia rates of just over 3% and of death from any cause of almost 4% among those who weren’t folate deficient.

After accounting for potentially influential factors, including co-existing diabetes, depression, cognitive decline, vitamin B12 deficiency, smoking and the use of folic acid supplements, the folate deficient were 68% more likely to be diagnosed with dementia and nearly 3 times as likely to die from any cause.

This is an observational study, and as such, can’t establish cause, particularly in light of the potential role of reverse causation, acknowledged the researchers. But it’s possible that folate deficiency might affect homocysteine levels and therefore the vascular risk of dementia, and/or compromise DNA repair of neurons, making them vulnerable to oxidative damage, which in turn might speed up brain cell ageing and damage, they explained.

They concluded, “Serum concentrations of folate may function as a biomarker used to modify the risks of dementia and mortality in old age,” adding that older adults should be routinely screened for folate deficiency.

“The implications for public health policy appear to be to reliably monitor serum concentrations of folate in older adults and treat deficiency for preventative measures and/or as part of implemented therapeutic strategies while regularly reviewing patients’ clinical outcomes,” they wrote.

Image credit: ©stock.adobe.com.au/godfather

Related News

10-second balance test could predict longevity: study

The inability to stand on one leg for 10 seconds in mid to later life is linked to an increased...

Mental health advocates must step up commitment, action: WHO

Their detailed report provides a blueprint for governments, academics, health professionals and...

Monash tech in PPD drug delivery milestone

A postpartum depression drug that currently must be administered as a 60-hour intravenous...

  • All content Copyright © 2022 Westwick-Farrow Pty Ltd